Patents Assigned to TOPOTARGET SWITZERLAND SA
-
Publication number: 20200095305Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.Type: ApplicationFiled: October 16, 2019Publication date: March 26, 2020Applicants: Biogen MA Inc., Topotarget Switzerland SAInventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
-
Patent number: 10494416Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.Type: GrantFiled: May 15, 2017Date of Patent: December 3, 2019Assignees: Biogen MA Inc., Topotarget Switzerland SAInventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
-
Publication number: 20180273605Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.Type: ApplicationFiled: May 15, 2017Publication date: September 27, 2018Applicants: Biogen MA Inc., Topotarget Switzerland SAInventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
-
Publication number: 20150139992Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.Type: ApplicationFiled: August 6, 2014Publication date: May 21, 2015Applicants: TOPOTARGET SWITZERLAND SA, BIOGEN IDEC MA INC.Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
-
Publication number: 20150098924Abstract: The present invention concerns a new method for ex-vivo purging of cells in autologous transplantation, wherein the sample of taken cells is treated with a sufficient amount of a multimeric form of the soluble portion of FasL to kill malignant cells without substantially affecting viability of cells to be transplanted. Autologous stem cell transplantation (ASCT) following high-dose chemotherapy with or without radiotherapy has become the standard therapy for the majority of patients with large-cell lymphomas, multiple myeloma, and refractory/recidivating Hodgkin's disease. Such therapy is nowadays also contemplated for selected patients with low-grade lymphomas (chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma) and for patients with acute myeloid leukemia (AML). Current treatments for cell purging include chemotherapy and antibody cocktails. These treatments are often toxic on stem cells and not efficient in eliminating cancer cells.Type: ApplicationFiled: October 9, 2013Publication date: April 9, 2015Applicant: Topotarget Switzerland SAInventors: Marc Dupuis, Peter Greaney, Michel Duchosal
-
Publication number: 20150004129Abstract: The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. The oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membranous signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence.Type: ApplicationFiled: April 29, 2014Publication date: January 1, 2015Applicant: TOPOTARGET SWITZERLAND SAInventors: Jurg TSCHOPP, Pascal SCHNEIDER, Nils HOLLER
-
Patent number: 8895003Abstract: Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular part of a TNF ligand as component (B) or a functional variant of component (B); and optionally (c) a transition area between component (A) and component (B), containing a linker.Type: GrantFiled: June 20, 2013Date of Patent: November 25, 2014Assignee: Topotarget Switzerland SAInventors: Olivier Gaide, Pascal Schneider, Jurg Tschopp
-
Patent number: 8501177Abstract: Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular part of a TNF ligand as component (B) or a functional variant of component (B); and optionally (c) a transition area between component (A) and component (B), containing a linker.Type: GrantFiled: April 8, 2010Date of Patent: August 6, 2013Assignee: Topotarget Switzerland SAInventors: Olivier Gaide, Pascal Schneider, Jurg Tschopp
-
Publication number: 20120009211Abstract: The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. Said oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membranous signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence.Type: ApplicationFiled: March 31, 2011Publication date: January 12, 2012Applicant: TOPOTARGET SWITZERLAND SAInventors: JÜRG TSCHOPP, PASCAL SCHNEIDER, NILS HOLLER
-
Publication number: 20110262449Abstract: The present invention relates to a new method, and the process to manufacture a medicament, for treating gout or pseudogout, comprising administering an effective amount of inhibitors blocking IL-1 or its maturation by the NALP3 inflammasome.Type: ApplicationFiled: July 1, 2011Publication date: October 27, 2011Applicant: TOPOTARGET SWITZERLAND SAInventors: Virginie PETRILLI, Fabio Martinon, Jurg Tschopp, Thibault De Smedt
-
Publication number: 20090325923Abstract: The present invention relates to the use of an inhibitor of the formation of nicotinamide adenyl dinucleotide for the preparation of a medicament used in the treatment of inflammatory diseases such as rheumatoid arthritis and endotoxemia.Type: ApplicationFiled: September 3, 2007Publication date: December 31, 2009Applicant: TOPOTARGET SWITZERLAND SAInventors: Oberdan Leo, Thibaut De Smedt, Frederic Van Gool, Mara Galli